By Denny Jacob
Keros Therapeutics' market value dived after the biopharmaceutical company said it halted dosing in a trial of a treatment for pulmonary arterial hypertension following unexpected, adverse pericardial-effusion events.
Shares of the Lexington, Mass., company were down 71% at $19.69 in premarket trading, nearly wiping out a 73% gain from the start of the year.
The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg dosages of cibotercept, in combination with background therapy.
Dosing in a 1.5 mg/kg arm of the trial will continue, the company said, adding it expected to present topline data from all arms of the trial in the second quarter of next year.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 12, 2024 07:38 ET (12:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。